Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9668 dose-ranging study in symptomatic COPD patients receiving tiotropium
2009-011148-21Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alvelestat in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by AstraZeneca. Primary endpoint: Pre-bronchodilator FEV1. Started Apr 2009; status: completed.
02
Drugs
alvelestat
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2009-011148-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011148-21.